Scalper1 News
Big biotech Amgen beat Wall Street’s Q3 estimates and offered mixed guidance late Wednesday, sending the stock up modestly in after-hours trading. Amgen (AMGN) reported adjusted earnings of $2.72 a share, up 18% from a year earlier and beating analysts’ consensus by 34 cents, according to Thomson Reuters. Revenue climbed 14% to $5.72 billion, about $400 million above consensus and the best gain in several years. Amgen lifted its Scalper1 News
Scalper1 News